Obesity Reframed: Dr. Sud Agarwal Breaks Down the Next Chapter in Obesity Therapeutics

For decades, obesity was boxed in as a lifestyle problem. It was treated more as a personal failing than a medical condition. But that lens is changing quickly, and not just in academic circles. Clinicians, regulators, and industry leaders are finally aligned on a critical shift: obesity is a chronic, relapsing disease that demands a structured clinical approach, targeted treatment strategies, and long-term support.

The Obesity Therapeutic Area Report presents one of the most detailed examinations to date of where the field stands, where it’s moving, and what the pharmaceutical industry can expect over the next five to ten years. From updated ICD-11 classifications to market-leading GLP-1 drugs and the future of combinatorial therapies, the report captures both the progress and the persistent challenges shaping obesity care.

The Redefinition of a Disease

Obesity now carries an official ICD-11 classification (5B81), a move that reflects mounting evidence and consensus that this is a disease with biological and environmental roots—not simply a reflection of individual behavior. The report highlights how diagnosis has expanded beyond BMI alone, factoring in waist circumference, waist-to-hip ratio, and the presence of metabolic comorbidities like hypertension and type 2 diabetes.

Still, BMI remains the standard diagnostic anchor. A BMI of 30 or above qualifies as obese, with stratifications across Class I, II, and III. Yet clinicians are increasingly moving toward a more nuanced assessment, incorporating cardiometabolic risk profiles and behavioral health indicators to personalize care.

A Growing Burden, Backed by Startling Data

Global obesity rates have more than tripled since the 1970s. In 2023, more than 650 million adults worldwide were classified as obese. In the United States, that figure is rising rapidly. More than 42 percent of American adults are now obese, and projections suggest nearly half the adult population will meet that threshold within the next decade.

These aren’t just numbers on a spreadsheet. The human and financial toll is staggering. Obesity increases the risk of heart disease, stroke, type 2 diabetes, and several forms of cancer. It also carries a heavy psychological and economic cost, reducing quality of life and workforce participation.

The report goes further by breaking down disparities by gender, age, ethnicity, and income. Women, particularly African American and Hispanic women, have significantly higher rates of severe obesity. Adolescents are now showing elevated BMI trends earlier than ever, especially in urban environments where sedentary lifestyles and processed foods are the norm.

Pharma’s Response: GLP-1s Change the Landscape

While the underlying causes of obesity are complex, drug development has made impressive strides in the past five years. The approval and commercial success of GLP-1 receptor agonists have shifted the treatment paradigm. Drugs like semaglutide (Wegovy) and liraglutide (Saxenda) have moved obesity into the realm of targeted medical therapy.

In clinical trials, semaglutide achieved nearly 15 percent average weight loss over 68 weeks. Saxenda showed similar metabolic improvements, especially among patients with type 2 diabetes. These therapies don’t just reduce weight. They improve cardiovascular markers, lower HbA1c, and help regulate hunger cues that are often biologically out of sync in patients with obesity.

Here’s a snapshot of where key obesity drugs stand in the U.S. market today:

These figures reflect more than earnings. They illustrate the demand for safe, effective long-term treatment options. That said, side effects like nausea and GI distress continue to affect adherence, especially in longer-term trials. The solution is often gradual dose escalation and strong patient education, both of which require coordination between prescribers, payers, and care teams.

Clinical Trials: Progress and Pitfalls

The report offers a clear-eyed view of what works and what doesn’t in obesity drug development. Several high-potential candidates have fallen short due to psychiatric side effects, cardiovascular risks, or lack of sustained efficacy. Rimonabant, Beloranib, and Lorcaserin (Belviq) all made headlines—until safety concerns shut them down.

Among the recurring challenges: strong placebo responses, inconsistent long-term adherence, and a tendency to exclude patients with complex comorbidities, which limits real-world applicability. Future trial protocols will need to address these shortcomings, particularly as regulators demand more robust post-marketing data to evaluate cardiovascular outcomes and cancer risk.

Some of the most important trials are now exploring broader endpoints: not just weight loss, but improvements in metabolic function, patient-reported outcomes, and quality of life metrics. This shift reflects the reality that obesity impacts more than just the scale.

What’s Ahead: Pediatric Focus, Emerging Drug Classes, and Minimally Invasive Options

Clinical attention is expanding to younger populations. Pediatric trials with semaglutide and liraglutide are showing promising results, opening doors to earlier intervention and long-term risk reduction. At the same time, new classes of obesity drugs are on the horizon. Dual agonists targeting both GLP-1 and GIP receptors are generating interest, along with agents that influence amylin or other hunger-regulating hormones.

Meanwhile, the popularity of bariatric surgery is being met with interest in less invasive procedures. Endoscopic sleeve gastroplasty and intragastric balloons are gaining traction for patients who don’t qualify for surgery but need more than lifestyle counseling.

Still, cost and access remain barriers. Many GLP-1s are expensive and not consistently covered by insurance, especially for obesity without comorbid diabetes. If these therapies are to reach their full impact, reimbursement policies will need to evolve alongside the science.

A Systems-Level Strategy Is Needed

The Obesity Therapeutic Area Report makes one thing clear: pharmacology alone won’t solve this crisis. Obesity is tied to the structure of society—food deserts, socioeconomic inequities, workplace stress, and sedentary urban life. Addressing the disease requires a coordinated effort across public health, private industry, and regulatory bodies.

What’s promising is that the industry is responding. Drug developers are aligning clinical endpoints with long-term outcomes. Regulators are pushing for inclusive trial designs and greater post-marketing surveillance. And there’s growing recognition that effective treatment must include behavioral support, nutritional education, and psychological care.

For those of us in medicine and biotech, this is a pivotal moment. The opportunity to redefine the standard of care is here. But we need to ensure that innovation doesn’t outpace accessibility or equity.

Obesity is not a temporary condition. It’s a lifelong disease that deserves a lifelong, science-backed strategy.